Consequently, restoring ACh levels has become a primary therapeutic strategy in AD therapeutics.[11] It is well established that two cholinesterase (ChE) enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), are responsible for the hydrolysis of ACh within the human brain. This evidence concerns the gene BCHE and Alzheimer disease.